Bergenfield, New Jersey Clinical Trials

A listing of Bergenfield, New Jersey clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 231 clinical trials
A First-in-human Study Using BDC-1001 in Advanced and HER2-Expressing Solid Tumors

A first-in-human study using BDC-1001 in HER2 expressing advanced malignancies

gene amplification
cancer
exhausted
measurable disease
HER2
Bolt Investigative Site
 (6.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +6 other locations
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers. The purpose of this study is to evaluate the safety and efficacy …

cancer
erbb1
blood test
measurable disease
growth factor
Hackensack Univ Med Ctr /ID# 216484
 (3.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +38 other locations
Dose Reduction of Postoperative Radiation for Soft Tissue Sarcoma of the Arms and Legs

The investigators are doing this study to find out whether lowering the dose of postoperative radiation therapy and targeting a smaller area of tissue for treatment is as effective as the standard dose and volume of radiation therapy to control soft tissue sarcoma after surgery. They also want to find …

soft tissue sarcoma
sarcoma
serum pregnancy test
sarcoma of the extremity
primary tumor
Memorial Sloan Kettering Bergen (All protocol activities)
 (9.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +6 other locations
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

platelet count
antineoplastic
antineoplastic agents
hras gene
corticosteroids
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
 (6.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +82 other locations
Targeted Fortification of Donor Breast Milk in Preterm Infants

This study is a randomized controlled trial comparing standard fortification of donor breast milk to targeted fortification of donor breast milk in preterm infants. The purpose of the study is to determine if there is a benefit to target fortifying donor breast milk in the preterm population. The investigators hypothesize …

Columbia University Medical Center/ New York - Presbyterian
 (6.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The …

imiglucerase
gaucher disease
eliglustat
deficiency
Investigational Site Number 840101
 (3.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +220 other locations
Mucopolysaccharidosis I (MPS I) Registry

The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients …

Investigational Site Number 840101
 (3.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +135 other locations
Pompe Disease Registry

The Pompe Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Pompe disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives …

replacement therapy
myozyme
glycogen storage disease type ii
gaa gene
deficiency
Investigational Site Number 840101
 (3.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +190 other locations
Fabry Disease Registry & Pregnancy Sub-registry

The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The primary …

replacement therapy
agalsidase beta
deficiency
alpha-galactosidase
fabrazyme
Investigational Site Number 840101
 (3.5 away) Contact site
  • 0 views
  • 05 Aug, 2024
  • +136 other locations
PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort

The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls The overall goal of …

parkinson's disease
modafinil
datscan
alpha-synuclein
bradykinesia
Columbia University Medical Center
 (6.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +45 other locations